| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC3543 |
| Trial ID | NCT05986864 |
| Disease | Age-Related Macular Degeneration |
| Altered gene | VEGFA |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | SKG0106 |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | A Multicenter, Open-label, Dose Escalation, Phase 1 Clinical Study and Randomized, Double-masked, Controlled, Dose Expansion Phase 2 Clinical Study to Evaluate the Safety, Preliminary Efficacy, Immunogenicity, and Pharmacokinetics of SKG0106 Intraocular Solution in Patients With Neovascular Age-related Macular Degeneration (nAMD) |
| Year | 2023 |
| Country | United States |
| Company sponsor | Skyline Therapeutics (US) Inc. |
| Other ID(s) | SKG0106-101 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||
|
|||||||